The administration of magnesium sulphate to mothers at risk for preterm birth for fetal
neuroprotection has demonstrated to reduce the risk of cerebral palsy and gross motor …

In women at risk of early preterm imminent birth, from viability to 30 weeks of gestation, use
of MgSO4 for neuroprotection of the fetus is recommended. In pregnancies below 32–34 …

Background Survival of preterm infants has improved drastically. In addition to significant
contribution to neonatal mortality, impact of prematurity among survivors may continue …

Introduction Preterm infants are at great risk of neurological impairments. This study aimed
to evaluate what is the difference in short-and long-term neonatal outcome comparing …

Magnesium is an essential component in the central nervous system and is irreplaceable in
several metabolic functions in the cell, therefore occupying a key place in cell death and …

Objective: To assess the effectiveness of magnesium sulfate as a neuroprotective agent in
early preterm labour (28 to 32 weeks). To assess any maternal or fetal adverse effects after …

METHODS OF STUDY SELECTION: Randomized controlled trials comparing magnesium
sulfate with placebo/other treatment in patients at risk of preterm delivery were evaluated for …

Background Magnesium sulphate is currently recommended for neuroprotection of preterm
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …

Magnesium sulfate has been administered to pregnant women at imminent risk of preterm
delivery for fetal neuroprotection, but its adverse effects and target population have not been …